164 related articles for article (PubMed ID: 18537606)
1. Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases.
Echaniz-Laguna A; Bousiges O; Loeffler JP; Boutillier AL
Curr Med Chem; 2008; 15(13):1263-73. PubMed ID: 18537606
[TBL] [Abstract][Full Text] [Related]
2. Histone acetylation as a potential therapeutic target in motor neuron degenerative diseases.
Garbes L; Riessland M; Wirth B
Curr Pharm Des; 2013; 19(28):5093-104. PubMed ID: 23448465
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibition activity and molecular docking of (e )-resveratrol: its therapeutic potential in spinal muscular atrophy.
Dayangaç-Erden D; Bora G; Ayhan P; Kocaefe C; Dalkara S; Yelekçi K; Demir AS; Erdem-Yurter H
Chem Biol Drug Des; 2009 Mar; 73(3):355-64. PubMed ID: 19207472
[TBL] [Abstract][Full Text] [Related]
4. The pharmaceutical potential of histone deacetylase inhibitors.
Elaut G; Rogiers V; Vanhaecke T
Curr Pharm Des; 2007; 13(25):2584-620. PubMed ID: 17897003
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy.
Lunke S; El-Osta A
J Neurochem; 2009 Jun; 109(6):1557-69. PubMed ID: 19383090
[TBL] [Abstract][Full Text] [Related]
6. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition.
Hauke J; Riessland M; Lunke S; Eyüpoglu IY; Blümcke I; El-Osta A; Wirth B; Hahnen E
Hum Mol Genet; 2009 Jan; 18(2):304-17. PubMed ID: 18971205
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors: overview and perspectives.
Dokmanovic M; Clarke C; Marks PA
Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
[TBL] [Abstract][Full Text] [Related]
8. Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.
Lai JI; Leman LJ; Ku S; Vickers CJ; Olsen CA; Montero A; Ghadiri MR; Gottesfeld JM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3289-3293. PubMed ID: 28648462
[TBL] [Abstract][Full Text] [Related]
9. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
10. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy.
Hahnen E; Eyüpoglu IY; Brichta L; Haastert K; Tränkle C; Siebzehnrübl FA; Riessland M; Hölker I; Claus P; Romstöck J; Buslei R; Wirth B; Blümcke I
J Neurochem; 2006 Jul; 98(1):193-202. PubMed ID: 16805808
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors in psoriasis therapy.
McLaughlin F; La Thangue NB
Curr Drug Targets Inflamm Allergy; 2004 Jun; 3(2):213-9. PubMed ID: 15180476
[TBL] [Abstract][Full Text] [Related]
12. [Motor neuron diseases. Present].
Pou A
Neurologia; 1996 Dec; 11 Suppl 5():1-6. PubMed ID: 9044569
[TBL] [Abstract][Full Text] [Related]
13. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy.
Tsai LK; Tsai MS; Lin TB; Hwu WL; Li H
Neurobiol Dis; 2006 Nov; 24(2):286-95. PubMed ID: 16952456
[TBL] [Abstract][Full Text] [Related]
14. Exploring Motor Neuron Diseases Using iPSC Platforms.
Johns AE; Maragakis NJ
Stem Cells; 2022 Mar; 40(1):2-13. PubMed ID: 35511862
[TBL] [Abstract][Full Text] [Related]
15. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
Gray SG; Dangond F
Epigenetics; 2006; 1(2):67-75. PubMed ID: 17998807
[TBL] [Abstract][Full Text] [Related]
16. Gene-based treatment of motor neuron diseases.
Federici T; Boulis NM
Muscle Nerve; 2006 Mar; 33(3):302-23. PubMed ID: 16228969
[TBL] [Abstract][Full Text] [Related]
17. TDP-43 in differential diagnosis of motor neuron disorders.
Dickson DW; Josephs KA; Amador-Ortiz C
Acta Neuropathol; 2007 Jul; 114(1):71-9. PubMed ID: 17569066
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
Zhou L; He X; Gao B; Xiong S
J Virol; 2015 Oct; 89(20):10512-23. PubMed ID: 26269170
[TBL] [Abstract][Full Text] [Related]
19. Mice, the motor system, and human motor neuron pathology.
Nicholson SJ; Witherden AS; Hafezparast M; Martin JE; Fisher EM
Mamm Genome; 2000 Dec; 11(12):1041-52. PubMed ID: 11130970
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
Kazantsev AG; Thompson LM
Nat Rev Drug Discov; 2008 Oct; 7(10):854-68. PubMed ID: 18827828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
